- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
EirGenix (6589)
Track today's live EirGenix (6589) share price, performance and key data on this page with our current Taiwan:6589 stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the EirGenix share price on the Taiwan exchange. Use the dropdown to switch exchange for the 6589 share price, head to our technical summary section, which provides analysis on EirGenix share price buy/sell indicators using real-time data (or discuss the EirGenix (6589) stock price today with other investors in the EirGenix TW share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current TW:6589 share price (ISIN: TW0006589005) to enhance your trading decisions with our free investment tools and resources.
What Is the EirGenix Share Price Today?
The EirGenix share price today is 48.70.
What Is the Stock Symbol for EirGenix
The stock symbol (or 'ticker') for EirGenix is "6589."
What Stock Exchange Does EirGenix Trade On?
EirGenix is listed and trades on the Taiwan stock exchange.
Is EirGenix a Good Stock to Buy?
Determining whether EirGenix (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current TW:6589 share price (ISIN: TW0006589005) to enhance your trading decisions with our free investment tools and resources.
What Is the EirGenix Share Price Today?
The EirGenix share price today is 48.70.
What Is the Stock Symbol for EirGenix
The stock symbol (or 'ticker') for EirGenix is "6589."
What Stock Exchange Does EirGenix Trade On?
EirGenix is listed and trades on the Taiwan stock exchange.
Is EirGenix a Good Stock to Buy?
Determining whether EirGenix (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Taiwan
Currency in TWD
48.70
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.30
49.30
52 wk Range
40.15
84.30
6589 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.3049.30
52 wk Range
40.1584.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
6589 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
111.00
Upside
+127.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 111.00
(+127.93% Upside)
Earnings
Latest Release
12/08/2026
EPS / Forecast
-0.70 / --
Revenue / Forecast
312M / --
Compare 6589 to Peers and Sector
Metrics to compare | 6589 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6589PeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.8x | 6.2x | −0.3x | |
PEG Ratio | 78.00 | 0.13 | 0.00 | |
Price/Book | 1.8x | 2.3x | 2.6x | |
Price / LTM Sales | 13.0x | 4.6x | 3.1x | |
Upside (Analyst Target) | 127.9% | −2.2% | 49.0% | |
Fair Value Upside | Unlock | 0.4% | 6.3% | Unlock |
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the EirGenix (Taiwan: 6589) Share Price Today?
The EirGenix stock price today is 48.70 TWD.
What Stock Exchange Does EirGenix (6589) Trade On?
EirGenix is listed and trades on the Taiwan Stock Exchange.
What Is the Ticker (Stock Symbol) for EirGenix?
The stock symbol (also called a 'ticker') for EirGenix is "6589."
What Is the Current EirGenix Market Capitalisation?
As of today, EirGenix (Taiwan: 6589) market cap is 14.75B TWD.
What Is EirGenix's (6589) Earnings Per Share (TTM)?
The EirGenix EPS is currently -2.47 (Trailing Twelve Months).
When Is the Next EirGenix Earnings Date?
EirGenix's next earnings report will be released on 18/11/2026.
Is 6589 a Buy or Sell From a Technical Analyst Perspective?
Based on today's EirGenix moving averages and other technical indicators, the daily buy/sell signal for 6589 stock is Neutral.
How Many Times Has EirGenix Stock Split?
EirGenix has split 4 times. (See the 6589 stock split history page for full effective split date and price information.)
How Many Employees Does EirGenix Have?
EirGenix has 1000 employees, based on their latest Companies House report.
What is the current trading status of EirGenix (Taiwan: 6589)?
As of 18/08/2026, EirGenix (6589) is trading at a share price of 48.70 TWD, with a previous close of 48.70 TWD. The stock has fluctuated within a day range of 48.30 TWD to 49.30 TWD, while its 52-week range spans from 40.15 TWD to 84.30 TWD.
What Is EirGenix (6589) Price Target According to Analysts?
The average 12-month price target for EirGenix is 111.00 TWD, with a high estimate of 111 TWD and a low estimate of 111 TWD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +127.93% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.